Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: A meta-analysis of clinical trial data

Pharmacopsychiatry

Volumn 38, Issue 2, 2005, Pages 69-77

  Brambilla, P ^a   Cipriani, A ^b   Hotopf, M ^c   Barbui, C ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYL 1 [(1,2,3,4 TETRAHYDRO 5,6 METHYLENEDIOXY 1 NAPHTHYL)METHYL]PYRROLIDINE; AMFEBUTAMONE; AMINEPTINE; AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; HYPERICUM EXTRACT; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NOMIFENSINE; NORTRIPTYLINE; PAROXETINE; PRAMIPEXOLE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; CHOLINERGIC ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DIARRHEA; DIZZINESS; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SUICIDE; SUICIDE ATTEMPT; SWEATING; TREATMENT WITHDRAWAL; TREMOR; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DRUG TOLERANCE; FLUOXETINE; GASTROINTESTINAL TRACT; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS;

EID: 15244347765     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-837806     Document Type: Article

References (23)

1. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Cmaj 1998; 159: 1245-52
2. Degner D, Grohmann R, Kropp S, Ruther E, Bender S, Engel RR et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 Suppl 1: S39-45
3. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Bmj 1995; 310: 1433-8
4. Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7 Suppl 1: 11-7
5. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36
6. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001; 57: 161-78
7. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001; 178: 129-44
8. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003; 326: 1-6
9. Barbui C, Guaiana G, Hotopf M. Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis. Pharmacopsychiatry 2004; 37: 93-7
10. Beasley CM Jr., Koke SC, Nilsson ME, Gonzales JS. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther 2000; 22: 1319-30
11. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728-33
12. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317: 1309-1312
13. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 507-33
14. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med 1986; 1: 155-8
15. Egger M, Smith GD, Sterne JA. Uses and abuses of meta-analysis. Clin Med 2001; 1: 478-84
16. Beasley CM Jr., Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr., Heiligenstein JH et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Bmj 1991; 303: 685-92
17. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003; 72: 71-9
18. Khan A, Khan S, Kolts R, Brown WA. Suicide Rates in Clinical Trials of SSRIs, Other Antidepressants, and Placebo: Analysis of FDA Reports. Am J Psychiatry 2003; 160: 790-2
19. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341-5
20. Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16: 355-365
21. Murray CY, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442
22. Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Huyser J. Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies. Pharmacopsychiatry 2004; 37: 32-6
23. Haberfellner EM, Rittmannsberger H. Spontaneous remission of SSRI-induced orgasm delay. Pharmacopsychiatry 2004; 37: 127-30